New Ultra-Fast Cancer Treatment ErSO-TFPy Promises Less Side Effects and Rapid Results in Less Than a Second
Jan 23, 2025, 03:02 AM
Recent research highlights a groundbreaking ultra-fast cancer treatment that could potentially replace conventional radiotherapy. This innovative approach, referred to as Flash Radiotherapy, promises to address a broader range of cancers while minimizing side effects and significantly reducing treatment time to less than a second. Additionally, a study on the drug candidate ErSO-TFPy has demonstrated its effectiveness in eradicating small breast cancer tumors in mice, indicating potential for treating estrogen receptor-positive breast cancer with minimal side effects. Further testing is required to confirm these findings and assess the treatments' applicability in clinical settings.
View original story
Markets
No • 50%
Yes • 50%
Announcements from pharmaceutical companies or clinical trial registries
No • 50%
Yes • 50%
Results published in peer-reviewed medical journals
Yes • 50%
No • 50%
FDA approval announcements
Less than 5 • 25%
More than 20 • 25%
11 to 20 • 25%
5 to 10 • 25%
Peer-reviewed medical journals or clinical guidelines
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Government health department announcements or regulatory agency approvals
Roche • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Announcements from pharmaceutical companies or clinical trial registries